Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Similar documents
EAE TEACHING COURSE Aorta and aortic valve 2012

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery

Aortic Valve Stenosis and CAD

Stress-echocardiography to guide decision making in valvular heart disease: Low-Flow, Low-Gradient Aortic Stenosis

Dysfunction of aortic valve prostheses

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

Note: The left and right sides of the heart must pump exactly the same volume of blood when averaged over a period of time

SECTION III: HEMODYNAMIC PRINCIPLES

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular

Fellow TEE Review Workshop Hemodynamic Calculations Director, Intraoperative TEE Program. Johns Hopkins School of Medicine

Aortic Stenosis and Comorbidities: the clinical challenge. P. Faggiano Cardiology Division Spedali Civili, Brescia - Italy

Disclosure. All the authors have no conflict of interest to disclose in this study.

INHERIT. The Lancet Diabetes & Endocrinology In press

Vs. K. Farsalinos, D. Tsiapras, S. Kyrzopoulos, M. Savvopoulou, E. Avramidou, D. Vassilopoulou, V. Voudris

Renal artery stenting: are there any indications left?

Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators

Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice

Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice

Normal ranges of left ventricular global longitudinal strain: A meta-analysis of 2484 subjects

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary

TAVR: A New Treatment Option for Aortic Stenosis. Alexis Auger, MSN, NP-BC

Riociguat Clinical Trial Program

How should we treat atrial fibrillation in heart failure

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code )

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

5. Management of rheumatic heart disease

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it.

Majestic Trial 12 Month Results

Diagnostic and Therapeutic Procedures

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Main Effect of Screening for Coronary Artery Disease Using CT

Atherosclerosis of the aorta. Artur Evangelista

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

CTA OF THE EXTRACORONARY HEART

Listen to your heart: Good Cardiovascular Health for Life

How To Treat Aortic Stenosis

Non-Invasive Positive Pressure Ventilation in Heart Failure Patients: For Who, Wy & When?

What Do You Mean by Aortic Valve Area: Geometric Orifice Area, Effective Orifice Area, or Gorlin Area? Damien Garcia, Lyes Kadem

Cardiogenic shock: invasive and non-invasive monitoring John T. Parissis Attikon University Hospital Athens, Greece

Section Four: Pulmonary Artery Waveform Interpretation

Cancer Treatment and the Heart Cardio-Oncology September 12, 2014

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Introduction to Cardiopulmonary Exercise Testing

Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013

The P Wave: Indicator of Atrial Enlargement

Atrial Fibrillation An update on diagnosis and management

INTRODUCTION TO EECP THERAPY

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

Inconsistencies in the Use of Cardiac Biomarkers or Echocardiography in Patients with Acute Non-Massive Pulmonary Embolism

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Ruchika D. Husa, MD, MS Assistant t Professor of Medicine in the Division of Cardiology The Ohio State University Wexner Medical Center

BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )

AORTIC STENOSIS. Marie-Jeanne Bertrand MD MSc

Name: Age: Resting BP: Wt. kg: Est. HR max : 85%HR max : Resting HR:

38 year old female with mild obesity. She is planning an exercise program to loose weight. She has no other known risk factors for CAD.

Statement on Disability: Pulmonary Hypertension

Objectives. The ECG in Pulmonary and Congenital Heart Disease. Lead II P-Wave Amplitude during COPD Exacerbation and after Treatment (50 pts.

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Edwards FloTrac Sensor & Edwards Vigileo Monitor. Measuring Continuous Cardiac Output with the FloTrac Sensor and Vigileo Monitor

Disclosures. Anesthesia and Lead Extractions. Lead Extractions: Objectives. Lead Removal Techniques. None

The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy

How do you decide on rate versus rhythm control?

Perioperative Cardiac Evaluation

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands

Anticoagulants in Atrial Fibrillation

Cardiogenic Shock + Critical Aortic Stenosis = Run the Other Way?!!!

RACE I Rapid Assessment by Cardiac Echo. Intensive Care Training Program Radboud University Medical Centre NIjmegen

1 Congestive Heart Failure & its Pharmacological Management

FFR CT : Clinical studies

Pre-Operative Cardiac Evaluation Kalpana Jain, MD

Predicting Aerobic Power (VO 2max ) Using The 1-Mile Walk Test

Atrial Fibrillation The Basics

Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI

on behalf of the AUGMENT-HF Investigators

Blood Pressure. Blood Pressure (mm Hg) pressure exerted by blood against arterial walls. Blood Pressure. Blood Pressure

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Introduction Hypothesis Methods Results Conclusions Figure 11-1: Format for scientific abstract preparation

Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014

CARDIAC RISKS OF NON CARDIAC SURGERY

Magnetic Resonance Quantitative Analysis. MRV MR Flow. Reliable analysis of heart and peripheral arteries in the clinical workflow

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

ECHOCARDIOGRAPHY PROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL CHAPTER 6. Hisham Dokainish, MD, FACC, FASE

Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital

Non-invasive functional testing in 2014

Transcription:

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None

77-year-old woman, mild dyspnea Body surface area = 1.77 m 2 LV ejection fraction = 60% (concentric hypertrophy) Aortic valve area = 0.9 cm 2 (0.5 cm 2 /m 2 ) Peak aortic jet velocity = 3.6 m/s Mean transaortic pressure gradient = 34 mm Hg Severe AS (AVA) with Low Gradient despite preserved LVEF : How should this patient be treated?

Paradoxical Low-Flow/ Low-Gradient AS - 512 patients (retrospective): AVA i 0.6 cm 2 /m 2, LVEF > 50% - Normal Flow (SVI > 35 ml/m 2 ) in 331 patients (65%) - Paradoxical Low Flow (SVI 35 ml/m 2 ) in 181 (35%) 4 Hachicha et al. Circulation. 2007;115:2856-64

Paradoxical Low-Flow/ Low-Gradient AS PLF : overall survival is impaired, compared with NF patients 5 Hachicha et al. Circulation. 2007;115:2856-64

Paradoxical Low-Flow/ Low-Gradient AS PLF : markedly lower survival if medically treated, as compared with those who underwent AVR 6 Hachicha et al. Circulation. 2007;115:2856-64

Henri Mondor Paradoxical Low-flow/ Low-gradient AS : Author s conclusions - Important proportion (35%) of patients with severe AS have Low-Flow / Low-Gradients despite preserved LVEF - Pattern associated with higher global LV afterload, severe LV concentric remodeling and lower survival, which suggests a more advanced stage of disease - This condition may often be misdiagnosed, which leads to underestimation of symptoms and inappropriate delay of surgery. Hachicha et al. Circulation. 2007;115:2856-64 7

Current echocardiographic criteria for the grading of AS Mild Moderate Severe AS Peak V < 3.0 m/s 3.0-4.0 m/s > 4.0 m/s Mean PG < 25 mm Hg 25-40 mm Hg > 40 mm Hg AVA > 1.5 cm² 1.0-1.5 cm² < 1.0 cm² Indexed AVA / / < 0.6 cm²/m² 9 ACC/ AHA Guidelines. J. Am. Coll. Cardiol. 2006;48: e1-148

Inconsistencies of echocardiographic criteria for the grading of AS Consistency of 3 criteria (AVA, Gradient, V max ) / Grading of AS - Analysis of 3483 Echo studies - 2427 patients, normal LV systolic function and AVA < 2.0 cm 2 - Gradient plotted vs. AVA (Gorlin formula) - Predicted curve: assuming CO = 6,0 L/min, HR = 80 bpm and SEP = 0.33 S 0.75 - Fitted curve : Actual data pairs 10 Minners et al. Eur Heart J. 2008;29:1043-8

Inconsistencies of echocardiographic criteria for the grading of AS - Peak Aortic-jet velocity is plotted vs. AVA (Continuity Equation) - Predicted curve: assuming standard LVOT diameter = 20 mm and LVOT peak velocity = 1,0 m/s - Fitted curve : Actual data pairs 0.80 11 Minners et al. Eur Heart J. 2008;29:1043-8

Inconsistencies of echocardiographic criteria for the grading of AS Possible overestimation of AS severity according to AVA criteria Study limitation: no outcome data to support a revision of the criteria for AS severity Minners et al. Eur Heart J. 2008;29:1043-8

Paradoxical Low-Flow/ Low-Gradient AS Variable Normal Flow (n= 331) Paradoxical Low Flow (n= 181) P value Adjusted P value MPG, mmhg 40±15 32±17 <0.001 <0.001 Body surf. area, m 2 1.8±0.2 1.8±0.2 NS NS LVOT diameter, mm 22±2 20±2 <0.001 0.04 Stroke Volume, ml 79±14 56±10 <0.001 NA Index AVA, cm 2/ m 2 0.46±0.08 0.42±0.11 <0.001 NS ZVA, mmhg/ml/m 2 4.1±0.7 5.3±1.3 <0.001 <0.001 14 Hachicha et al. Circulation. 2007;115:2856-64

Henri Mondor The critical issue of LVOT diameter measurement Underestimation of LVOT diameter is 1 Error leading to underestimation of AVA May also lead to underestimate stroke volume and to the false conclusion of Low-Flow LVOT diameter should be re-checked (several times) on closer examination Current values: 20±2 mm (women) and 22±3 mm (men) ** TEE may be useful in case of poor image quality N. Jander. Eur Heart J. 2008; 10 (Suppl E): E11-15 ** European Registry on LGAS. Unpublished 15

Underestimated LVOT diameter leads to overestimation of AS severity 16 AVA = 0.9 cm 2 AVA = 1.2 cm 2

Paradoxical Low-Flow/ Low-Gradient AS The signs of AS severity (i.e. high pressure gradients) can be masked by the presence of concomitant hypertension, particularly if associated with a significant decrease in systemic arterial compliance Blood pressure may be pseudo normalized in patients with high hemodynamic load and low stroke volume Dumesnil et al. Eur Heart J. 2010; 31 : 281-9

Systemic pressure does not directly affect MPG and AVA estimates in AS In vitro model of AS, AVA = 1.0 cm 2, constant flow rate = 2.0 L/min: Systolic pressure = 80 mmhg Systolic pressure = 80 mmhg Systolic pressure = 200 mmhg Systolic pressure = 200 mmhg Computed modeling of velocity (left) and absolute pressure (right) Mascherbauer et al. Eur Heart J. 2008;29:2049-57

Systemic pressure does not directly affect MPG and AVA estimates in AS In vitro model of AS, AVA = 1.0 cm 2, constant flow rate = 2.0 L/min: Blood pressure itself does not directly affect pressure gradients in AS. Low gradient is most likely due impaired LV systolic function (afterload mismatch) with decrease in stroke volume Mascherbauer et al. Eur Heart J. 2008;29:2049-57

77-year-old woman, AS / mild dyspnea

LVEF = 60% (Biplane Simpson)

Speckle tracking : longitudinal strain Global longitudinal strain is markedly decreased (-12%) : normal values -20%

LVEF of 50% may represent systolic dysfunction in the setting of severe AS with concentric hypertrophy in this case, Low-flow is neither unexpected nor paradoxical N. Jander. Eur Heart J. 2008; 10 (Suppl E): E11-15

Paradoxical Low-flow AS : Impairment of intrinsic LV function 120 consecutive Pts, index AVA <0.6 cm 2 /m 2 and LVEF> 50%, 2D-Strain analysis Patients with PLF have impaired LV myocardial function evidenced by speckle tracking imaging Mielot et al. Eur Heart J. 2009; 30 (Abstract Suppl ): 683

Comprehensive evaluation of aortic stenosis severity - Systemic arterial compliance - systemic vascular resistance - valvulo-arterial impedance - LVEF (Simpson + Dumesnil) - Mid-wall fractional shortening This will add little time to the examination (?) Peripheral blood pressure should be recorded in every patient Dumesnil et al. Eur Heart J. 2010; 31 : 281-9

Valvulo-arterial Impedance (Zva): Do we need a new Concept? Clinical implications - Zva does not account separately for the valvular vs. arterial component of LV afterload - Therefore, High Zva may reflect either: 1/ Moderate AS with severe hypertension, requiring Blood pressure control 2/ Truly severe AS requiring valve replacement - In current practice, we can still rely on simple measures of AS severity (peak velocity, gradient, AVA), as long as we also consider blood pressure and cardiac output H. Baumgartner & CM. Otto. J Am Coll Cardiol. 2009;54: 1012-3

Assessment of valve calcification by TTE : Look at the valve! 1/ No calcification 2/ Mildly calcified (isolated, small spots), 3/ Moderately calcified (multiple bigger spots) 4/ Heavily calcified (extensive thickening/ calcification of all cusps). Rosenhek et al. N Engl J Med. 2000;343:611

Incremental value of serum BNP over peak aortic-jet velocity Prospective study, 211 asymptomatic patients (72 years [63-77]) with moderate / severe AS Gender Age, years Peak Velocity, m/s Serum BNP, pg/ml Risk Score FU Duration, Months Cause of Death Male 84 3.4 521 16.1 (Q3) 9 CHF Male 77 4.0 123 15.2 (Q3) 6 Pulmonary Edema Female 49 4.8 116 18.3 (Q4) 19 Sudden death 31 Monin et al. Circulation. 2009; 120: 69-75

77-year-old woman, mild dyspnea LV ejection fraction = 60% Global longitudinal strain = - 11% Aortic valve area = 0.9 cm 2 (0.5 cm 2 /m 2 ) Mean transaortic pressure gradient = 34 mm Hg Severe aortic valve calcification BNP = 450 pg/ ml Valve replacement was performed Uncomplicated course thereafter

Take-Home messages Some cases of Low-Flow / Low-gradient AS may be due to: - Underestimation of LVOT diameter, leading to underestimation of stroke volume and AVA - Inconsistencies of current criteria for defining AS severity The prevalence of this clinical entity may not be as high as 30% (probably less than 10%) Uncontrolled hypertension participates in global LV overload and thus, should be adequately treated

Take-Home messages Low-flow/ Low-gradient AS with preserved LVEF is due to intrinsic myocardial dysfunction, as evidenced by Speckle Tracking imaging Valvulo-arterial impedance is unable to differentiate the respective burden of aortic stenosis vs. arterial load Valve calcification and serum BNP may be helpful for clinical decision making